Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

25.48 +0.19 (+0.75%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since ↗
Via MarketBeat
News headline image
Why Pfizer (PFE) Shares Are Sliding Today
Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed... 
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
News headline image
Ozempic Maker Novo Nordisk Faces Board Shakeup ↗
Novo Nordisk faces board changes, investor friction and bold M&A moves as leadership pushes to regain momentum in the obesity drug market. 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗
 
Via Benzinga
News headline image
Novo Nordisk Stock Falls Premarket As Investors Brace For Contentious Vote To Reinstate Former CEO ↗
The board overhaul follows mass resignations triggered by internal disputes over Novo’s direction. 
Via Stocktwits
News headline image
Pfizer Stock Slips Premarket Despite Completing Metsera Deal; Investors React To BioNTech Stake Cut ↗
The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 nearing Phase 3. 
Via Stocktwits
Topics Intellectual Property
Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium ↗
Via Stocktwits
News headline image
AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This... 
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Post-Shutdown Jitters: Markets Reel as Government Reopens
The United States government, after an unprecedented 43-day shutdown, officially reopened on Thursday, November 13, 2025, as President Donald Trump signed a funding bill into law. While the resolution... 
Via MarketMinute
Topics Bonds Economy Government
News headline image
Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗
The company now plans to submit the data from the study to regulatory authorities. 
Via Stocktwits
News headline image
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session. ↗
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention. 
Via Chartmill
News headline image
Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report ↗
CEO Albert Bourla told Yahoo Finance that the acquisition of GLP-1 maker Metsera is part of the company's "right to win" in the obesity drug game. 
Via Stocktwits
News headline image
Pfizer Completes Acquisition of Metsera
From Pfizer Inc.
Via Business Wire
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
BioNTech Says Collaboration With Pfizer Going Strong After Report Indicated US Pharma Giant Considering Stake Sale In The German Company ↗
A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.” 
Via Stocktwits
News headline image
Should You Forget Pfizer and Buy This Magnificent Drug Stock Instead? ↗
Pfizer has a huge dividend yield and a high payout ratio compared to Merck, which could make Merck the more attractive dividend stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Viking Therapeutics Stock Soars To 10-Month High After Canaccord Boost – Retail Traders See It As Next Big Obesity Play ↗
Canaccord said Viking’s obesity pipeline is worth far more than the current valuation. 
Via Stocktwits
News headline image
Reflecting On Generic Pharmaceuticals Stocks’ Q3 Earnings: Viatris (NASDAQ:VTRS)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Healthcare Stocks Topping a 2025 List of Dividend Yields ↗
Turn health into wealth with these three high-yielding dividend stocks. 
Via The Motley Fool
News headline image
Curious about the most active S&P500 stocks in today's session? ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
News headline image
Dow Soars to New Record High as Government Shutdown Nears End
New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) surged by nearly 400 points today, hitting an unprecedented record high, as investors enthusiastically embraced the impending... 
Via MarketMinute
Topics Economy Government Stocks
News headline image
Looking Into Pfizer Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the... 
Via MarketMinute
Topics Initial Public Offering Intellectual Property Regulatory Compliance
News headline image
2 Strong Healthcare Stock Picks for Value Investors ↗
Value-driven plays abound in the top healthcare stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Santa Claus Rally: 3 Discounted Stocks Heading Into 2026 ↗
Pfizer’s comeback, Newmont’s resilience, and Utz’s growth positioning make them compelling candidates for year-end gains. 
Via Talk Markets
News headline image
Why Metsera's Share Price Is Plummeting This Week ↗
The biotech start-up's stock had been rising rapidly in 2025. 
Via The Motley Fool
News headline image
3 Unprofitable Stocks That Concern Us
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.